Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marc Port has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Sophie Laurent

    Laboratory of NMR and Molecular Imaging, Department of General, Organic and Biomedical Chemistry, University of Mons, B-7000 Mons, Belgium

    4 shared publications
  • Catherine Gomez

    Laboratoire de Génomique, Bioinformatique et Chimie Moléculaire (EA 7528), Equipe Chimie Moléculaire, Conservatoire National des Arts et Métiers (Cnam), HESAM Université, 2 rue Conté, 75003 Paris, France

    3 shared publications
  • Maité Sylla-Iyarreta Veitía

    Equipe de Chimie Moléculaire du Laboratoire Génomique, Bioinformatique et Chimie Moléculaire (EA 7528), Conservatoire National des Arts et Métiers (Cnam), 2 Rue Conté, HESAM Université, 75003 Paris, France

    3 shared publications
  • Aïda Mascret

    Equipe de Chimie Moléculaire du Laboratoire Génomique, Bioinformatique et Chimie Moléculaire (EA 7528), Conservatoire National des Arts et Métiers (Cnam), 2 rue Conté, HESAM Université, Paris 75003, France

    2 shared publications
  • Carine San

    Conservatoire national des arts et métiers Laboratoire Génomique, bioinformatique et chimie moléculaire (GBCM) EA 7528 2 rue Conté 75003 Paris France

    2 shared publications
  • Chouki Zerrouki

    SATIE, UMR CNRS 8029, Cnam, 75003 Paris, France

    2 shared publications

Latest Publications

  • The Discovery of Gadopiclenol: An Example of Rational Drug Design?

    by Marc Port

    Gadopiclenol was initially developed as a high-relaxivity, nonspecific magnetic resonance imaging contrast agent to enhance image quality and thereby improve diagnostics. This design required a highly demanding Drug Target Profile, addressing not only relaxivity but also factors such as physicochemical properties of the injectable solution (viscosity, osmolality, heat sterilization compatibility), pharmacokinetics and toxicity, particularly related to the stability of the complex. These considerations led to a multiparametric molecular design based on a gadolinium complex characterized by the following features: (1) a macrocyclic, nonionic structure based on the PCTA framework with 2 water molecules in the inner sphere; (2) the introduction of steric constraints around the gadolinium to enhance stability and reduce relaxivity quenching by endogenous ions; (3) slowed rotational diffusion due to gadolinium's position at the center of the complex; and (4) the incorporation of 3 hydrophilic amino polyol pendant arms to ensure aqueous solubility, reduce binding with endogenous proteins, and enhance product safety. This rational design led to the creation of a first prototype, P03277V1. However, the occurrence of nephrogenic systemic fibrosis necessitated modifications to the Drug Target Profile, aimed at improving the complex's stability and reducing production costs. This was achieved through the discovery of an isomerization process for P03277V1, resulting in gadopiclenol, which demonstrated excellent kinetic stability. The rational design of gadopiclenol thus exemplifies the concept of Property-Based Drug Design used in medicinal chemistry. It also highlights that the complexity of designing a diagnostic agent is comparable to that of a therapeutic agent. Furthermore, the case of gadopiclenol illustrates that the medical positioning of a drug candidate can evolve during clinical development. Gadopiclenol's medical positioning shifted from being a product with high relaxivity to improve signal strength, to one intended for use at a half dose to limit gadolinium injection and minimize risks to patients, such as nephrogenic systemic fibrosis or accumulation in specific areas of the brain. Currently, gadopiclenol is approved for clinical use at a dose of 0.05 mmol/kg to minimize gadolinium exposure to patients. Whether the 0.1 mmol/kg dose can be used to enhance clinical diagnostics and improve patient management in the future remains to be seen.


  • Open Access

    Bifunctional Hexadentate Pyclen–Based Chelating Agent for Mild Radiofluorination in Aqueous Solution at Room Temperature with a Ga‐18F Ternary Complex

    by Fabienne Dioury, Carine San, Gayathiri Gnanalingam, Céline Henoumont, Yoann Rousselin, Ahmed Haouz, William Shepard, Benoît Hosten, Kamsana Vijayakumar, Sophie Laurent, et al.

    Positron Emission Tomography (PET) is used in oncology for tumor diagnosis, commonly relying on fluorine‐18 (18F) emission detection. The conventional method of 18F incorporation on to probes by covalent bonding is harsh for sensitive biomolecules, which are nonetheless compounds of choice for the development of targeted probes. This study explores gallium–18F (Ga18F) coordination, a milder alternative method occurring in aqueous media at the final stage of radiosyntheses. Pyclen‐based chelating agents were proposed to capture (GaF) species at room temperature and pH≥5 making the radiofluorination process compatible with heat‐ and acid‐sensitive biomolecules. Highly promising results were obtained with the PC2A–based chelating agent LH2 derived from the new bifunctional PC2A–OAE–NCS compound. The solid‐state structure of GaF(L) was elucidated by X‐ray diffraction and revealed an unconventional heptacoordination of Ga(III). A high radiochemical conversion (RCC) of 86 % was achieved at room temperature, in water at pH 5 within 20 minutes. Stability studies showed the robustness of the GaF(L) complex in aqueous media for at least one day and at least one hour for the radiolabeled analog Ga18F(L). These findings demonstrated that PC2A‐based compounds are chelating agents of choice for (Ga18F) species, suggesting a real technological breakthrough for PET imaging and precision medicine.


  • Open Access

    Optimization of a 1,4,7‐Triazacyclononane‐1,4‐diacetic acid (NODA) Derivative Radiofluorination by Al18F Complexation Using a Design of Experiments Approach

    by Carine San, Benoît Hosten, Nicolas Vignal, Meriem Beddek, Maurice Pillet, Laure Sarda‐Mantel, Marc Port, Fabienne Dioury

    Fluorine‐18 (18F) is the most favorable positron emitter for radiolabeling Positron Emission Tomography (PET) probes. However, conventional 18F labeling through covalent C−F bond formation is challenging, involving multiple steps and stringent conditions unsuitable for sensitive biomolecular probes whose integrity may be altered. Over the past decade, an elegant new approach has been developed involving the coordination of an aluminum fluoride {Al18F} species in aqueous media at a late‐stage of the synthetic process. The objective of this study was to implement this method and to optimize radiolabeling efficiency using a Design of Experiments (DoE). To assess the impact of various experimental parameters on {Al18F} incorporation, a pentadentate chelating agent NODA‐MP‐C4 was prepared as a model compound. This model carried a thiourea function present in the final conjugates resulting from the grafting of the chelating agent onto the probe. The formation of the radioactive complex Al18F‐NODA‐MP‐C4 was studied to achieve the highest radiochemical conversion. A complementary “cold” series study using the natural isotope 19F was also conducted to guide the radiochemical operating conditions. Ultimately, Al18F‐NODA‐MP‐C4 was obtained with a reproducible and satisfactory radiochemical conversion of 79±3.5 % (n=5).


  • Open Access

    Performances of Homogeneous and Heterogenized Methylene Blue on Silica Under Red Light in Batch and Continuous Flow Photochemical Reactors

    by Maxime Lancel, Catherine Gomez, Marc Port, Zacharias Amara

    Methylene blue was efficiently immobilized on silica micro- and nanoparticles by electrostatic interactions and the performances of the heterogenized photocatalysts were compared against the homogeneous conditions using the photooxidation of citronellol as a model reaction under red light, in a batch and a continuous flow photochemical reactor. In batch, the heterogeneous photocatalyst outperforms the homogeneous one, presumably due to kinetic and stability effects. The two catalytic systems are also compared in a flow reactor displaying improved mass transfer properties. We demonstrate that this results in a dramatic enhancement in photocatalyst stability, reactivity and productivity. This study highlights the importance of photocatalyst stability under homogeneous versus heterogenized conditions and in batch versus flow photochemistry.


  • Open Access

    Data of the quantification of the influence of DMSO concentration on the kinetic of interaction between TNFα and SPD304

    by Ghada Attia, Aïda Mascret, Chouki Zerrouki, Najla Fourati, Maité Sylla-Iyarreta Veitía, Marc Port

  • Open Access

    Characterization of Organic Molecules Grafted to Silica or Bismuth Nanoparticles by NMR

    by Céline Henoumont, Gauthier Hallot, Estelle Lipani, Catherine Gomez, Robert N. Muller, Luce Vander Elst, Marc Port, Sophie Laurent

    NMR is a powerful characterization tool and we propose to study the surface of silica or bismuth nanoparticles dedicated to medical applications in order to evidence the covalent grafting of organic molecules on their surface. For that aim, DOSY experiments are particularly useful and allow for the discrimination of molecules interacting strongly with the nanoparticle surface from molecules simply weakly adsorbed at the surface. We were able to characterize thoroughly the surface of different silica and bismuth nanoparticles.

  • Open Access

    Medical Applications of Metallic Bismuth Nanoparticles

    by Catherine Gomez, Gauthier Hallot, Sophie Laurent, Marc Port

    Recent reviews described the efficient syntheses of metallic bismuth nanoparticles. Nevertheless, few studies have been published on the medical applications of these nanoparticles compared to the number of studies on the well-documented clinical use of the bismuth(III) complex. An analysis of the literature revealed the significant potential of metallic bismuth nanoparticles in different theranostic applications. In the diagnostic field, preclinical proofs of concept have been demonstrated for X-ray, photoacoustic and fluorescence imaging. In the therapeutic field, several preclinical studies have shown the potential of bismuth nanoparticles as X-ray radiosensitizers for use in radiotherapy and as photothermal agents for applications in near infrared phototherapy. The properties of these metallic bismuth nanoparticles as bactericidal, fungicidal, antiparasitic and antibiofilm agents have also been studied. Although information concerning the toxic effects of these nanoparticles has been collected, these data are insufficient when considering the immediate clinical use of these new nanoparticles.


  • New contributions to the drug profile of TNFα inhibitor SPD304: Affinity, selectivity and ADMET considerations

    by Aïda Mascret, Hadley Mouhsine, Ghada Attia, Damien Cabrera, Mohamed Benchekroun, Patrick Gizzi, Chouki Zerrouki, Najla Fourati, Jean-François Zagury, Maité Sylla-Iyarreta Veitía, et al.


  • Open Access

    Molecular Imaging of Galectin-1 Expression as a Biomarker of Papillary Thyroid Cancer by Using Peptide-Functionalized Imaging Probes

    by Deborah Fanfone, Dimitri Stanicki, Denis Nonclercq, Marc Port, Luce Vander Elst, Sophie Laurent, Robert N. Muller, Sven Saussez, Carmen Burtea

    Thyroid cancers are the most frequent endocrine cancers and their incidence is increasing worldwide. Thyroid nodules occur in over 19–68% of the population, but only 7–15% of them are diagnosed as malignant. Diagnosis relies on a fine needle aspiration biopsy, which is often inconclusive and about 90% of thyroidectomies are performed for benign lesions. Galectin-1 has been proposed as a confident biomarker for the discrimination of malignant from benign nodules. We previously identified by phage display two peptides (P1 and P7) targeting galectin-1, with the goal of developing imaging probes for non-invasive diagnosis of thyroid cancer. The peptides were coupled to ultra-small superparamagnetic particles of iron oxide (USPIO) or to a near-infrared dye (CF770) for non-invasive detection of galectin-1 expression in a mouse model of papillary thyroid cancer (PTC, as the most frequent one) by magnetic resonance imaging and fluorescence lifetime imaging. The imaging probes functionalized with the two peptides presented comparable image enhancement characteristics. However, those coupled to P7 were more favorable, and showed decreased retention by the liver and spleen (known for their galectin-1 expression) and high sensitivity (75%) and specificity (100%) of PTC detection, which confirm the aptitude of this peptide to discriminate human malignant from benign nodules (80% sensitivity, 100% specificity) previously observed by immunohistochemistry.